Sequent Scientific Ltd.

NSE: SEQUENT | BSE: 512529 | ISIN: INE807F01027 |Industry: Pharmaceuticals
|Expensive Star
145.40 1.75 (1.22%)
NSE Oct 30, 2020 10:34 AM
Volume: 154.0K

Sequent Scientific Ltd.    
14 Nov 2019
Nirmal Bang Institutional
Sequent Scientific or SSL's 2QFY20 revenue at Rs2,842mn was in line with our estimate. Revenue grew by 14.5% YoY (cc) and was primarily led by growth in API sales. API sales grew by 30% YoY and now contribute 33% to total sales. The growth in API sales should sustain at least until the end of FY21 as the company expects to monetize its niche VMF (Veterinary master files) filings with low competitive intensity. About 5 of the 17 VMF filings of Sequent Formulations are niche, where SSL is the only filer. Formulation sales grew slower at 8% during the quarter as the company's largest geography Europe underperformed and declined 2.5% YoY. The decline in Europe is transient and was...
Sequent Scientific L.. has an average target of 146.33 from 3 brokers.
More from Sequent Scientific Ltd.